|
On The Fly
| ShowHide Related Items >><< - 05/13/22
- Starboard takes stake in Humana, exits System1
- 04/19/22
- System1 falls -33.8%
- 04/19/22
- System1 falls -28.6%
- 04/19/22
- System1 falls -25.8%
- 05/10/22
- SoFi Technologies off lows after resumption, remains down 13%
- 05/10/22
- SoFi Technologies trading resumes
- 05/10/22
- SoFi Technologies to resume trading at 2:10 pm ET
- 05/10/22
- SoFi Technologies CEO says 'off to a great start' standing up bank
- 05/19/22
- Sweetgreen rises 15.7%
- 03/23/22
- Sweetgreen to open 'sweetlane' restaurant concept in Schamuburg, IL
- 03/04/22
- Sweetgreen rises 18.1%
- 03/04/22
- Sweetgreen rises 13.3%
RSI Rush Street Interactive - 04/04/22
- Rush Street Interactive launches BetRivers online casino, sportsbook in Ontario
- 03/31/22
- Rush Street Interactive receives RG Check iGaming Accreditation from RGC
- 03/22/22
- Rush Street Interactive signs Mike Francesa to brand, content deal
- 03/10/22
- Rush Street Interactive receives iGaming operator registration from AGCO
- 05/16/22
- Rocket Lab begins payload integration for Capstone mission to the Moon
- 05/03/22
- Rocket Lab announces successful launch of 26th Electron mission
- 04/19/22
- Rocket Lab secures multi-launch contract with HawkEye 360
- 04/07/22
- Rocket Lab names Arjun Kampani as General Counsel
- $194.98 /
-15.34 (-7.29%) - 05/03/22
- MicroStrategy names Andrew Kang CFO
- 04/05/22
- MicroStrategy acquired 4,167 bitcoins for $190.5M in cash
- 03/29/22
- MicroStrategy borrows $205M from Silvergate to buy more bitcoin
- 03/09/22
- Biden to sign executive order on 'responsible innovation' in digital assets
- 04/28/22
- Krystal Biotech's Jeune Aesthetics announces formation of SAB
- 04/11/22
- Krystal Biotech announces home dosing in B-VEC open label extension study
- 03/28/22
- Krystal Biotech announces publication of Phase 1, 2 trial data of B-VEC
- 03/22/22
- Jeune Aesthetics announces clinical Phase 1 efficacy data for KB301
- 04/27/22
- GDS Holdings, YTL partner on 168MW data center development
- 12/17/21
- Freshpet down 12% at $83.75 after cutting FY21 guidance on supply chain issues
- 11/30/21
- Freshpet CEO buys $200K in common stock
CYXT Cyxtera Technologies - 05/16/22
- Soros Capital buys Suncor and Mosaic during Q1, exits Alphabet
- 05/12/22
- Cyxtera Technologies expands to India via partnership with Sify Technologies
- 05/18/22
- Canopy Growth announces plans to acquire Jetty Extracts
- 04/26/22
- Canopy Growth expects to generate savings of $100M-$150M within 12-18 months
- 04/26/22
- Canopy Growth announces cost reduction initiatives including headcount reduction
- 03/31/22
- Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO
- 01/10/22
- Pfizer, Beam Therapeutics announce four-year research collaboration
- 12/12/21
- Beam outlines long-term strategy for base editing programs in SCD
- 05/02/22
- AST receives experimental license from FCC for BlueWalker 3 satellite
- 04/29/22
- AST SpaceMobile announces Sean Wallace as CFO
- 04/28/22
- AST SpaceMobile enters collaboration with Globe Telecom
- 04/28/22
- AST SpaceMobile announces MoU with Globe Telecom
- 05/19/22
- Jack Henry & Associates, Array announce collaboration
- 04/25/22
- Array Technologies provides statement on US Department of Commerce decision
- 04/05/22
- Array Technologies appoints Kevin Hostetler as CEO
- 04/04/22
- Array to supply advanced tracker technology for solar storage project in US
- 03/22/22
- Baker Hughes collaborates with C3.ai, Accenture and Microsoft on IAM solutions
- 03/07/22
- C3.ai, LyondellBasell expand strategic pact for acceleration of enterprise AI
- 02/16/22
- C3.ai down 7% after Spruce Point makes short call, sees 40%-50% downside
- 02/16/22
- C3.ai drops 7% to $23.87 after Spruce Point short report
- 05/17/22 Mizuho
- SoFi Technologies price target lowered to $9 from $14 at Mizuho
- 05/16/22 Piper Sandler
- Piper upgrades SoFi to buy ahead of 'significant' earnings ramp
- 05/16/22 Piper Sandler
- SoFi Technologies upgraded to Overweight from Neutral at Piper Sandler
- 05/12/22 Citi
- SoFi Technologies price target lowered to $11 from $17 at Citi
- 05/20/22 Alliance Global Partners
- Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
- 04/04/22 Morgan Stanley
- Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 03/22/22 Barclays
- Canopy Growth downgraded to Underweight from Equal Weight at Barclays
- 05/20/22 Atlantic Equities
- Atlantic Equities sees more volatility for Freshpet, downgrades shares
- 05/20/22 Atlantic Equities
- Freshpet downgraded to Neutral from Overweight at Atlantic Equities
- 05/03/22 Cowen
- Freshpet price target lowered to $163 from $181 at Cowen
- 05/03/22 Oppenheimer
- Freshpet price target lowered to $110 from $120 at Oppenheimer
- 04/28/22 Credit Suisse
- Beam Therapeutics initiated with a Neutral at Credit Suisse
- 01/10/22 Wedbush
- Beam Therapeutics price target raised to $159 from $148 at Wedbush
- 01/05/22 Guggenheim
- Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
- 01/05/22 Guggenheim
- Beam Therapeutics initiated with a Buy at Guggenheim
- 04/26/22 Evercore ISI
- System1 initiated with an In Line at Evercore ISI
- 04/06/22 DA Davidson
- System1 price target raised to $26 from $23 at DA Davidson
- 04/06/22 Benchmark
- System1 'more than a meme,' but trading likely to stay volatile, says Benchmark
- 11/29/21 DA Davidson
- Trebia Acquisition initiated with a Buy at DA Davidson
- 05/03/22 Wedbush
- Wedbush downgrades C3.ai to Neutral, lowers price target to $16
- 05/03/22 Wedbush
- C3.ai downgraded to Neutral from Outperform at Wedbush
- 03/25/22 Morgan Stanley
- C3.ai price target lowered to $20 from $31 at Morgan Stanley
- 03/04/22 Deutsche Bank
- Deutsche downgrades C3.ai to Sell, says 'all is not well'
- 03/29/22 Guggenheim
- Krystal Biotech price target lowered to $101 from $114 at Guggenheim
- 02/28/22 H.C. Wainwright
- Krystal Biotech price target lowered to $107 from $124 at H.C. Wainwright
- 01/18/22 BofA
- Krystal Biotech initiated with a Buy at BofA
- 01/18/22 BofA
- Krystal Biotech initiated with a Buy at BofA
- 04/01/22 Deutsche Bank
- AST SpaceMobile price target lowered to $32 from $35 at Deutsche Bank
- 07/12/21 Barclays
- AST SpaceMobile initiated with an Overweight at Barclays
- 06/30/21 Deutsche Bank
- AST SpaceMobile initiated with a Buy at Deutsche Bank
RSI Rush Street Interactive - 04/27/22 Wells Fargo
- Wells Fargo upgrades Rush Street Interactive to Overweight, lowers target to $10
- 04/27/22 Wells Fargo
- Rush Street upgraded to Overweight from Equal Weight at Wells Fargo
- 03/10/22 Benchmark
- Rush Street Interactive price target lowered to $16 from $27 at Benchmark
- 03/03/22 Oppenheimer
- Rush Street Interactive price target lowered to $11 from $14 at Oppenheimer
- $194.98 /
-15.34 (-7.29%) - 05/16/22 Jefferies
- MicroStrategy does not face liquidity, solvency risk, says Jefferies
- 05/13/22 William Blair
- MicroStrategy can 'comfortably' support interest payments, says William Blair
- 05/04/22 Canaccord
- MicroStrategy price target lowered to $453 from $540 at Canaccord
- 02/02/22 Canaccord
- MicroStrategy price target lowered to $540 from $871 at Canaccord
- 04/12/22 Citi
- Sweetgreen initiated with a Neutral at Citi
- 03/17/22 Cowen
- Cowen favors domestic restaurant chains as inflation hurts sector
- 03/04/22 Morgan Stanley
- Morgan Stanley says first post-IPO report a positive for Sweetgreen shares
- 03/04/22 Oppenheimer
- Sweetgreen price target lowered to $37 from $41 at Oppenheimer
- 05/12/22 Truist
- Array Technologies price target lowered to $8 from $14 at Truist
- 05/11/22 Roth MKM
- Array Technologies downgraded to Neutral from Buy at Roth Capital
- 05/02/22 Truist
- Array Technologies assumed with a Hold at Truist
- 04/21/22 Piper Sandler
- Array Technologies price target lowered to $12 from $16 at Piper Sandler
CYXT Cyxtera Technologies - 04/07/22 Cowen
- Cyxtera Technologies lack of asset ownership limits valuation, says Cowen
- 04/07/22 Credit Suisse
- Cyxtera Technologies initiated with an Outperform at Credit Suisse
- 01/28/22 William Blair
- Cyxtera Technologies initiated with an Outperform at William Blair
- 01/06/22 Cowen
- Cyxtera Technologies initiated with an Outperform at Cowen
- 05/19/22 Truist
- GDS Holdings price target lowered to $75 from $85 at Truist
- 05/19/22 Cowen
- GDS Holdings price target lowered to $47 from $53 at Cowen
- 05/19/22 Raymond James
- GDS Holdings price target lowered to $55 from $68 at Raymond James
- 05/16/22 Credit Suisse
- GDS Holdings price target lowered to $48.90 from $71.50 at Credit Suisse
- 05/17/22 Canaccord
- Rocket Lab price target lowered to $16 from $28 at Canaccord
- 05/17/22 Deutsche Bank
- Rocket Lab price target lowered to $14 from $18 at Deutsche Bank
- 02/23/22 Roth MKM
- Rocket Lab initiated with a Buy at Roth Capital
- 01/28/22 Deutsche Bank
- Rocket Lab most promising rocket company after SpaceX, says Deutsche Bank
- 04/04/22
- System1 sees FY22 revenue $1B
- 04/04/22
- System1 reports Q4 revenue $238.9M vs. $160.9M last year
- 05/10/22
- SoFi Technologies sees FY22 adjusted revenue $1.505B-$1.51B, consensus $1.46B
- 05/10/22
- SoFi Technologies sees Q2 adjusted net revenue $330M-$340M, consensus $343.9M
- 05/10/22
- SoFi Technologies reports Q1 EPS (14c), consensus (14c)
- 05/10/22
- SoFi Technologies sees FY22 adjusted revenue $1.51B, Bloomberg says
- 05/05/22
- Sweetgreen backs FY22 revenue view $515M-$535M, consensus $530.53M
- 05/05/22
- Sweetgreen reports Q1 EPS (45c), consensus (41c)
- 03/04/22
- Sweetgreen sees Q1 revenue $100M-$102M, consensus $101.24M
- 03/04/22
- Sweetgreen sees FY22 revenue of $515M-$535M, consensus $513.12M
RSI Rush Street Interactive - 05/04/22
- Rush Street raises 2022 sales outlook to $600M-$650M from $580M-$530M
- 05/04/22
- Rush Street Interactive reports Q1 EPS (24c), consensus (19c)
- 03/02/22
- Rush Street Interactive sees 2022 revenue $580M-$630M, consensus $611.04M
- 03/02/22
- Rush Street Interactive reports Q4 adjusted EPS (15c), consensus (11c)
- 05/16/22
- Rocket Lab sees Q2 revenue $51M-$54M, consensus $59.2M
- 05/16/22
- Rocket Lab reports Q1 EPS (6c), consensus (4c)
- 02/28/22
- Rocket Lab sees Q1 revenue $42M-$47M, consensus $55M
- $194.98 /
-15.34 (-7.29%) - 05/03/22
- MicroStrategy reports Q1 adjusted EPS ($10.42), two estimates $1.41
- 02/01/22
- MicroStrategy reports Q4 EPS ($8.43), consensus $1.49
- 02/28/22
- Krystal Biotech reports Q4 EPS (94c), consensus (73c)
- 05/19/22
- GDS Holdings backs FY22 revenue view of RMB 9.32B - RMB 9.68B
- 05/19/22
- GDS Holdings reports Q1 EPS (50c), consensus (25c)
- 03/22/22
- GDS Holdings sees 2022 revenue RMB 9.32B - RMB 9.68B
- 03/22/22
- GDS Holdings reports Q4 EPS (30c), consensus (18c)
- 05/02/22
- Freshpet backs FY22 revenue view at least $575M, consensus $576.99M
- 05/02/22
- Freshpet reports Q1 EPS (40c), consensus (39c)
- 02/28/22
- Freshpet sees FY22 revenue $575M, consensus $562.4M
- 02/28/22
- Freshpet reports Q4 EPS (21c), consensus (16c)
CYXT Cyxtera Technologies - 05/12/22
- Cyxtera Technologies sees 2022 revenue $730M-$760M, consensus $745.8M
- 05/12/22
- Cyxtera Technologies reports Q1 EPS (23c), consensus (22c)
- 03/22/22
- Cyxtera Technologies sees FY22 revenue $730M-$760M, consensus $729.56M
- 03/22/22
- Cyxtera Technologies reports Q4 EPS (40c), consensus (26c)
- 04/07/22
- Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55
- 02/09/22
- Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago
- 05/09/22
- Beam Therapeutics reports Q1 EPS ($1.01), consensus ($1.32)
- 02/28/22
- Beam Therapeutics reports Q4 EPS (95c), consensus ($1.03)
- 05/10/22
- Array Technologies lowers FY22 adjusted EPS 25c-35c from 55c-74c, consensus 56c
- 05/10/22
- Array Technologies reports Q1 adjusted EPS (2c), consensus (6c)
- 04/05/22
- Array Technologies sees FY22 adjusted EPS 55c-74c, consensus 66c
- 04/05/22
- Array Technologies reports Q4 adjusted EPS (6c), consensus (3c)
- 03/02/22
- C3.ai raises FY22 revenue view to $251M-$252M from $248M-$251M
- 03/02/22
- C3.ai reports Q3 adjusted EPS (7c), consensus (27c)
- 12/01/21
- C3.ai sees FY22 revenue $248M-$251M, consensus 246.0M
- 12/01/21
- C3.ai sees Q3 revenue $66M-$68M, consensus $65.64M
|
